欧美日韩视频

Rockville, MD (April 20, 2026) - In response to the new Executive Order titled “,” and ongoing public discourse on the research of psychedelics like ibogaine for the treatment of opioid use disorder (OUD), Stephen M. Taylor, MD, MPH, DFAPA, DFASAM, president of the American Society of Addiction Medicine (ASAM), issued the following statement:

“ASAM appreciates federal efforts to advance scientific research on treatments for OUD. However, the pursuit of investigational treatments, such as psychedelics like ibogaine, should not pull our attention away from currently available medications that can save lives.

FDA-approved medications for the treatment of OUD, such as methadone, buprenorphine, and naltrexone, have a strong evidence base, are proven to reduce morbidity and mortality, and should be available to patients when clinically appropriate.

Today, methadone and buprenorphine remain first-line treatments for active OUD. Ibogaine should not be considered a substitute for these proven treatments at this time.

Ibogaine’s potential for the treatment of OUD will be evaluated through ongoing and future research, which should be held to the highest level of scientific rigor and meet robust patient safety and efficacy requirements. In the meantime, patients and healthcare professionals should remain informed about FDA-approved, evidence-based medication treatments for OUD.”

# # #

Media Contact

Sarah Shelson

301-547-4110 

sshelson@ASAM.org